Blow For Prestige As Trastuzumab Biosimilar Rejected By EMA

Tuznue And Hervelous Rivals To Herceptin Receive Negative Opinions From CHMP

 
• By David Wallace
  
EU flag thumbs down
The CHMP has refused to endorse Prestige Biopharma’s trastuzumab • Source: Shutterstock

More from Biosimilars

More from Products